Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label booster safety study of S-268019 in adults previously vaccinated against COVID-19
jRCT2031210613Phase 3Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Feb 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of S-268019-b in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Shionogi & Co., Ltd. Primary endpoint: Safety. Started Feb 2022; status: completed.
02
Drugs
S-268019-b
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031210613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210613.